Table 1 Basic data of demographic, clinical and laboratory characteristics of 22 AAV patients treated with RTX or CYC
Characteristics | RTX (n = 8) | CYC (n = 14) | P value |
|---|---|---|---|
Patients’ characteristic | |||
Age at first treatment (y) | 61.5 ± 13.2 | 60.9 ± 6.6 | 0.879 |
Gender(M/F) | 3/5 | 6/8 | 0.670 |
onset / relapse | 6/2 | 14/0 | 0.121 |
Comorbidities | |||
Hypertension, n (%) | 3(37.5) | 3(21.4) | 0.624 |
Diabetes mellitus | 1(12.5) | 4(28.6) | 0.613 |
Tobacco | 1(12.5) | 5(35.7) | 0.351 |
Lung involvement, n (%) | 3(37.5) | 7(50%) | 0.675 |
Other organs involvement, n(%) | none | Joints, 3 (21.4%) | 0.273 |
Laboratory parameters | |||
Serum albumin (g/L) | 27.7 ± 4.4 | 28.4 ± 4.3 | 0.739 |
Serum creatinine (μmol/L), median (IQR) | 267.8 (167.7, 562.6) | 297.3 (245.4, 490.7) | 0.920 |
eGFR (ml/min/1.73m2), median (IQR) | 17.7 (6.5, 32.6) | 14.9 (8.7, 19.3) | 0.973 |
24 h urine protein (g), median (IQR) | 2.0(1.1, 3.7) | 2.1(1.1, 3.4) | 0.920 |
PR3-ANCA/ MPO-ANCA | 0/8 | 1/13 | 1.000 |
Immunoglobulin G (g/L), median (IQR) | 1555.0 (1090.0, 2117.5) | 1490.0 (1051.5, 2220.0) | 0.804 |
Immunoglobulin A (g/L), median (IQR) | 255.0 (180.3, 464.3) | 304.0 (212.5, 352.5) | 0.916 |
Immunoglobulin M (g/L), median (IQR) | 87.5 (59.1, 105.0) | 68.2 (53.9, 147.0) | 0.916 |
C3 (mg/dl), median (IQR) | 90.9 (62.6, 100.0) | 82.7 (68.4, 92.2) | 0.595 |
Hypocomplementemia C3, n (%) | 3 (37.5) | 3 (21.4) | 0.624 |
C4 (mg/dl), median (IQR) | 20.3 (15.6, 30.8) | 21.81 (15.2, 24.4) | 0.972 |
Hemoglobin (g/L), median (IQR) | 109.5 (101.0, 140.8) | 104.5 (96.3, 112.5) | 0.165 |
CD4 + T cells (/μL), median (IQR) | 1018.5 (451.25, 1356.25) | 616 (500.75, 840.5) | 0.238 |
CD19 + B cells(/μL), median (IQR) | 315.0 (204.0, 455.0) | 385.5 (112.25, 507.75) | 1.000 |
B1 CD19 + CD5 + | 21.0 (8.0, 59.0) | 45.5 (9.0, 100.25) | 0.628 |
B2 CD19 + CD5- | 288.0 (196.0, 396.0) | 332.5 (94.75, 419.75) | 0.836 |
Histopathologic classification [9] | |||
Focal, n (%) | 3 (50) | 3(37.5) | |
Crescentic, n (%) | 3 (50) | 5(62.5) | |
Mixed, n (%) | 0 | 0 | |
Sclerotic, n(%) | 0 | 0 | |
IF/TA > 25%, n (%) | 6 (100) | 8 (100) | |
BVAS | 17.5 ± 4.0 | 17.0 ± 2.9 | 0.761 |
Main treatments | |||
Corticosteroids | 8 (100%) | 14 (100%) | 1.000 |
MP Pulse (500 mg/d*3d) | 1 (12.5%) | 5 (35.7%) | 0.351 |
Plasmapheresis | |||
Number of patients | 3 (37.5%) | 6 (42.9%) | 1.000 |
Median (range) | 5 (5, 5) | 6.5 (4.5, 9.25) | 0.429 |
Intravenous immunoglobulin | |||
Number of patients | 3 (37.5%) | 4 (28.6%) | 1.000 |